# Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer

> **NCT03151447** · PHASE1 · UNKNOWN · sponsor: **Fudan University** · enrollment: 18 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **RADIATION:** stereotactic body radiation therapy

## Key facts

- **NCT ID:** NCT03151447
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-06
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03151447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03151447, "Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03151447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*